Jennifer L. Good Sells 10,981 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock

Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Jennifer L. Good sold 10,981 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total transaction of $33,162.62. Following the transaction, the chief executive officer now owns 213,313 shares of the company’s stock, valued at approximately $644,205.26. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Trevi Therapeutics Stock Down 4.8 %

Shares of TRVI opened at $2.95 on Friday. The stock has a market cap of $214.14 million, a P/E ratio of -8.68 and a beta of 0.96. The business’s fifty day moving average is $2.87 and its 200 day moving average is $2.87. Trevi Therapeutics, Inc. has a 12-month low of $0.97 and a 12-month high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). During the same quarter in the previous year, the company earned ($0.07) EPS. On average, analysts expect that Trevi Therapeutics, Inc. will post -0.47 EPS for the current year.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds have recently bought and sold shares of the company. American Century Companies Inc. raised its holdings in shares of Trevi Therapeutics by 17.1% in the second quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after purchasing an additional 7,902 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Trevi Therapeutics by 87.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after buying an additional 11,450 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of Trevi Therapeutics during the first quarter valued at approximately $47,000. Hsbc Holdings PLC purchased a new position in Trevi Therapeutics in the second quarter worth $61,000. Finally, Rhumbline Advisers grew its stake in Trevi Therapeutics by 44.8% in the 2nd quarter. Rhumbline Advisers now owns 75,218 shares of the company’s stock valued at $224,000 after purchasing an additional 23,263 shares during the period. 95.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on TRVI shares. Raymond James began coverage on shares of Trevi Therapeutics in a research report on Friday, August 30th. They set an “outperform” rating and a $9.00 price objective for the company. HC Wainwright initiated coverage on Trevi Therapeutics in a research note on Friday, August 30th. They issued a “buy” rating and a $6.00 price objective on the stock. EF Hutton Acquisition Co. I raised Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, August 19th. Finally, Rodman & Renshaw began coverage on Trevi Therapeutics in a research note on Thursday, June 13th. They issued a “buy” rating and a $7.00 price target on the stock. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $7.80.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.